| pubmed-article:3316049 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3316049 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:3316049 | lifeskim:mentions | umls-concept:C0019764 | lld:lifeskim |
| pubmed-article:3316049 | lifeskim:mentions | umls-concept:C0079731 | lld:lifeskim |
| pubmed-article:3316049 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:3316049 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:3316049 | lifeskim:mentions | umls-concept:C0063356 | lld:lifeskim |
| pubmed-article:3316049 | lifeskim:mentions | umls-concept:C0332183 | lld:lifeskim |
| pubmed-article:3316049 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:3316049 | pubmed:dateCreated | 1987-12-21 | lld:pubmed |
| pubmed-article:3316049 | pubmed:abstractText | The expression of HLA-DR, HLA-DP and HLA-DQ antigens was studied in an unselected series of 66 B-cell lymphomas by means of immunohistology using monoclonal antibodies against non-polymorphic determinants in a sensitive immunoperoxidase technique. In addition, the expression of the MHC class-II antigen-associated invariant chain (li) was examined. The tumors were classified according to the Kiel classification, 30 being of high-grade and 36 being of low-grade malignancy. Only 6 lymphomas of high-grade and 16 lymphomas of low-grade malignancy showed coordinate strong expression of all HLA class-II antigens and invariant chain as observed in the normal peripheral B cell. Six further tumors of high-grade and 8 tumors of low-grade malignancy contained tumor-cell subsets with reduced expression of one or several of the antigens. Eighteen lymphomas of high-grade and 12 lymphomas of low-grade malignancy contained varying tumor-cell subsets that were negative for HLA-DR, -DP, -DQ and li in a selective or combined manner. Three highly malignant tumors were devoid of all class-II antigens and li; 2 highly malignant tumors expressed invariant chain only. The presence of high-grade malignancy was significantly correlated with the occurrence of tumor cells lacking HLA-DR (p = 0.004), HLA-DP (p = 0.013), HLA-DQ (p = 0.007) or li (p = 0.024). | lld:pubmed |
| pubmed-article:3316049 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3316049 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3316049 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3316049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3316049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3316049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3316049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3316049 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3316049 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:3316049 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:3316049 | pubmed:author | pubmed-author:HerrmannBB | lld:pubmed |
| pubmed-article:3316049 | pubmed:author | pubmed-author:MöllerPP | lld:pubmed |
| pubmed-article:3316049 | pubmed:author | pubmed-author:MoldenhauerGG | lld:pubmed |
| pubmed-article:3316049 | pubmed:author | pubmed-author:MomburgFF | lld:pubmed |
| pubmed-article:3316049 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3316049 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:3316049 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:3316049 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3316049 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3316049 | pubmed:pagination | 598-603 | lld:pubmed |
| pubmed-article:3316049 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:meshHeading | pubmed-meshheading:3316049-... | lld:pubmed |
| pubmed-article:3316049 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3316049 | pubmed:articleTitle | B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain. | lld:pubmed |
| pubmed-article:3316049 | pubmed:affiliation | Institute of Pathology, University of Heidelberg, FRG. | lld:pubmed |
| pubmed-article:3316049 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3316049 | lld:pubmed |
